Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935126 · ClinicalTrials.gov registry record
Global Atrophie Biomarker Evaluation Study (GABiE)
A clinical trial, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- 3
- Enrollment target
NCT03935126: Clinical Trial study, sponsored by Boehringer Ingelheim.
NCT03935126 is a clinical trial that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03935126 was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.
Interventions
- DIAGNOSTIC_TEST Diagnostics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-05-07 |
| Est. Completion | 2020-05-14 |
Why NCT03935126 stopped before completion
NCT03935126 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Diagnostics is the first listed.
NCT03935126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03935126 about?
NCT03935126 is a clinical study titled "Global Atrophie Biomarker Evaluation Study (GABiE)". To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.
What is the current status of trial NCT03935126?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2019-05-07. Estimated completion is 2020-05-14.
What interventions are being tested in trial NCT03935126?
The interventions under investigation include: Diagnostics (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03935126?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI